Stock 301301 YILI CHUANNING BIOTECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Yili Chuanning Biotechnology Co.,Ltd.

Equities

301301

CNE100005WX0

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
13.52 CNY -0.59% Intraday chart for Yili Chuanning Biotechnology Co.,Ltd. +1.96% +60.95%
May. 14 Yili Chuanning Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2023 CI
Apr. 21 Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
YILI CHUANNING BIOTECHNOLOGY CO.,LTD. Stock Yili Chuanning Biotechnology Co.,Ltd.
+60.95% 4.15B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.31% 795B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.33% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.31% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.50% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.68% 294B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.00% 245B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.23% 222B
A+
NOVARTIS AG Stock Novartis AG
+12.03% 215B
B-
AMGEN INC. Stock Amgen Inc.
+3.59% 160B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 301301 Stock
  4. Ratings Yili Chuanning Biotechnology Co.,Ltd.